Filtered By:
Condition: Bleeding
Education: Academia

This page shows you your search results in order of relevance. This is page number 13.

Order by Relevance | Date

Total 422 results found since Jan 2013.

SOURCE 3 Registry: Design and 30-Day Results of the European Post Approval Registry of the Latest Generation of the Sapien 3TM Transcatheter Heart Valve.
CONCLUSIONS: -Results from the SOURCE 3 Registry demonstrate contemporary European trends and good outcomes of TAVI in daily practice when using this third generation TAVI device. PMID: 28104716 [PubMed - as supplied by publisher]
Source: Circulation - January 18, 2017 Category: Cardiology Authors: Wendler O, Schymik G, Treede H, Baumgartner H, Dumonteil N, Ihlberg L, Neumann FJ, Tarantini G, Zamorano JL, Vahanian A Tags: Circulation Source Type: research

Early Clinical Outcomes After Transcatheter Aortic Valve Replacement Using a Novel Self-Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Who Are Suboptimal for Surgery: Results of the Evolut R U.S. Study
Conclusions We conclude that this novel self-expanding TAV bioprosthesis is safe and effective for the treatment of patients with severe aortic stenosis who are suboptimal for surgery. (Medtronic CoreValve Evolut R U.S. Clinical Study; NCT02207569).
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - February 5, 2017 Category: Cardiology Authors: Popma, J. J., Reardon, M. J., Khabbaz, K., Harrison, J. K., Hughes, G. C., Kodali, S., George, I., Deeb, G. M., Chetcuti, S., Kipperman, R., Brown, J., Qiao, H., Slater, J., Williams, M. R. Tags: Structural Source Type: research

Thrombotic valvular dysfunction with transcatheter mitral interventions for postsurgical failures
ConclusionThrombotic related dysfunction post‐TMVR occurred in 15% (2/13) of patients and one patient had abnormal leaflet thickening that may have been thrombus related. Dual‐antiplatelet therapy was used in all 3 cases suggesting the possible need for oral anticoagulation postmitral valve‐in‐valve therapy. © 2017 Wiley Periodicals, Inc.
Source: Catheterization and Cardiovascular Interventions - February 9, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Marvin H. Eng, Adam Greenbaum, Dee Dee Wang, Janet Wyman, DNP, Heider Arjomand, Pradeep Yadav, Hassan Nemeh, Gaetano Paone, Mayra Guerrero, William O'Neill Tags: Valvular and Structural Heart Diseases Source Type: research

Association of Measured Platelet Reactivity with Changes in P2Y12 Receptor Inhibitor Therapy and Outcomes Following Myocardial Infarction: Insights into Routine Clinical Practice from the TRANSLATE-ACS Study
Conclusions Only one-third of PCI-treated MI patients with high on-clopidogrel platelet reactivity were switched to a more potent P2Y12 receptor inhibitor. Intensification of antiplatelet therapy was associated with lower risk of ischemic events at 1year among HPR patients.
Source: American Heart Journal - February 10, 2017 Category: Cardiology Source Type: research

Gender related differences in antiplatelet treatment patterns and outcome: insights from the GreekAntiPlatElet(GRAPE) Registry
ConclusionsIn a contemporary ‘real life’ cohort of ACS patients treated with PCI and focusing on antiplatelet treatment one‐year ischemic outcome does not differ by gender, while women do present more frequently not actionable bleeding events.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - April 1, 2017 Category: Cardiology Authors: I. Xanthopoulou, P. Davlouros, S. Deftereos, M. Hamilos, G. Sitafidis, I. Kanakakis, M. Vavouranakis, J. Goudevenos, J. Lekakis, D. Alexopoulos Tags: Original Research Article Source Type: research

Prevalence of Bleeding Complications Following Ultrasound-Guided Botulinum Toxin Injections in Patiens on Anticoagulation or Antiplatelet Therapy
Conclusions The risk of clinically significant bleeding complication appears to be very small following ultrasound-guided intramuscular chemodenervation procedures in the setting of systemic anticoagulation or antiplatelet therapy.
Source: PMandR - June 17, 2017 Category: Rehabilitation Source Type: research

Gender ‐related differences in antiplatelet treatment patterns and outcome: Insights from the GReekAntiPlatElet Registry
ConclusionsIn a contemporary “real‐life” cohort of patients with ACS treated with PCI and focusing on antiplatelet treatment 1‐year ischemic outcome does not differ by gender, while women do present more frequently not actionable bleeding events.
Source: Cardiovascular Therapeutics - July 14, 2017 Category: Cardiology Authors: Ioanna Xanthopoulou, Periklis Davlouros, Spyridon Deftereos, Michalis Hamilos, George Sitafidis, Ioannis Kanakakis, Manolis Vavouranakis, John Goudevenos, John Lekakis, Dimitrios Alexopoulos Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study
Conclusion: HOPE-TAILOR is a prospective, randomized, open-label, blinded, endpoint study to explore the efficacy and safety of novel P2Y12 receptor inhibitors administered orally at half the dose in Korean patients with ACS. The results will be available late in 2017.Cardiology 2017;138:201-206
Source: Cardiology - August 15, 2017 Category: Cardiology Source Type: research

FDA approves pivotal study of Vascular Dynamics MobiusHD high blood pressure device
Vascular Dynamics said today that the FDA approved an investigational device exemption for a clinical trial of its MobiusHD device for treating resistant hypertension. MobiusHD is designed to help regulate blood pressure using electrodes implanted in the carotid artery to stimulate baroreceptors there. Mountain View, Calif.–based Vascular Dynamics said the 300-patient Calm 2 study is designed to compare treatment with MobiusHD and a sham procedure. The primary safety endpoint is a composite of death, myocardial infarction, stroke, device embolization, carotid occlusion, new ipsilateral carotid stenosis requiring surgic...
Source: Mass Device - August 15, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Clinical Trials Food & Drug Administration (FDA) Regulatory/Compliance vasculardynamics Source Type: news

Vascular complications after balloon aortic valvuloplasty in recent years: Incidence and comparison of two hemostatic devices
ConclusionsVC rate after BAV is fairly low in experienced centers without major differences between the 2 most used VCD.
Source: Catheterization and Cardiovascular Interventions - October 5, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Gianni Dall'Ara, Andrea Santarelli, Antonio Marzocchi, Maria Letizia Bacchi Reggiani, Maria Rita Sabattini, Carolina Moretti, Cinzia Marrozzini, Nevio Taglieri, Federica Baldazzi, Nicoletta Franco, Paolo Ortolani, Matteo Chiarabelli, Giulio Rodin ò, Gian Tags: VALVULAR AND STRUCTURAL HEART DISEASES Source Type: research

Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study
ConclusionA switched DAPT is superior to an unchanged DAPT strategy to prevent bleeding complications without increase in ischaemic events following ACS.
Source: European Heart Journal - May 16, 2017 Category: Cardiology Source Type: research

Impact of active cancer disease on the outcome of patients undergoing transcatheter aortic valve replacement
ConclusionThe presence of ACD in patients undergoing TAVR is associated with significantly higher 1‐year mortality.
Source: Journal of Interventional Cardiology - November 22, 2017 Category: Cardiology Authors: Norman Mangner, Felix J. Woitek, Stephan Haussig, David Holzhey, Georg Stachel, Florian Schlotter, Robert H öllriegel, Friedrich W. Mohr, Gerhard Schuler, Axel Linke Tags: ORIGINAL INVESTIGATION Source Type: research

Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials.
CONCLUSION: In patients with ACS, both prasugrel and ticagrelor showed similar adverse cardiovascular outcomes and bleeding events. No significant difference was observed between these two newer antiplatelet agents during this head to head comparison. However, upcoming trials with long term follow up periods might be expected to completely solve this important clinical issue. PMID: 29233189 [PubMed - in process]
Source: BMC Pharmacology and Toxicology - December 15, 2017 Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research

Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy
Conclusion In ‘real-life’ ACS undergoing PCI, diabetic patients have higher – although not significantly – MACE rate and no difference in bleeding events. This difference in MACE was significant among clopidogrel-treated patients, whereas when newer antiplatelet agents were used the negative impact of DM on ischemic events was eliminated.
Source: Coronary Artery Disease - December 19, 2017 Category: Cardiology Tags: Original Research Source Type: research

Percutaneous coronary intervention without P2Y12 inhibitor pretreatment: A real-life study
Conclusions In an unselected population admitted for elective PCI or NSTEMI in real-life practice, administration of a P2Y12 inhibitor only after coronary angiography is associated with a low rate of ischaemic and bleeding events at 30 days.
Source: Archives of Cardiovascular Diseases Supplements - January 5, 2018 Category: Cardiology Source Type: research